Fact CheckerSign in

NCT06092372Completed

The Role of Genetics in Weight Loss

The Role of Genetics in Weight Loss: a Randomized Diet Intervention Study in Individuals With High or Low Genetic Risk for Obesity (GENEROOS Study)

Source: ClinicalTrials.gov · Last updated 29 Jan 2026

Brief summary (registry, in English)

The prevalence of both overweight and obesity is increasing at an alarming rate worldwide. In fact, it is estimated that 2.16 billion adults (38%) will be overweight and 1.12 billion adults (20%) will be obese by 2030. Among other risk factors (e.g., environmental, behavioral, and medical), genetics holds an important role. Genome-wide association studies have discovered hundreds of loci associated with body mass index (BMI). Polygenic scores (PS) are generated from a combination of millions of genetic variants that are associated with BMI. Several diet intervention studies aimed at reducing body weight in overweight and obese individuals. However, the effect of genetic background on the effectiveness of diet interventions is largely unknown. To our knowledge, the Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) trial is the only prospective study that has been designed to evaluate the effect of genotypes in modifying the impact of a healthy low-fat diet vs a healthy low-carbohydrate diet on weight change, but this study did not consider PS. The aim of our study is to determine whether BMI PS impacts the effectiveness of dietary intervention in reducing BMI among individuals with elevated BMI. To achieve this, the investigators will leverage the unique opportunity provided by the Finnish biobanks research environment to re-contact 1200 individuals who have extreme genetic predisposition for high/low BMI as measured by a PS for BMI and evaluate how a randomized diet intervention effect varies between the two extreme groups. In brief, the investigators will invite overweight (25-35 BMI) individuals with very high (Top 5%; n=600) and very low (Bottom 5%; n=600) PS for BMI. Half of the participants in each group will be subsequently randomized to enroll in a dietary/lifestyle coaching intervention program or the placebo group and not receive any dietary advice or information. All participants will be asked to answer an online questionnaire and provide a fasting blood sample at baseline and at the end of the study. This well-powered prospective study leverages the unique opportunity to re-contact individuals at the extremes of BMI PS from a large pool of individuals with already available genetic information. This study will determine whether BMI PS can be used to identify overweight and obese individuals who are more likely to succeed in a reduced-energy dietary intervention, which will assist our efforts in curbing the overweight and obesity epidemic.

Status (registry)
Completed
Study type
Interventional
Enrollment
223 (actual)
First submitted
11 Oct 2023
Start date
2 Oct 2023
Primary completion date
8 Nov 2024
Lead sponsor
University of Helsinki
Diseases
Obesity
NCT number
NCT06092372

What you commit to

  • Study type: Interventional
  • Participants enrolled: 223
  • From 2 Oct 2023 to the primary completion date, 8 Nov 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • diagnosis of type I and II Diabetes Mellitus
  • history of bariatric surgery
  • diagnosis of dementia and Parkinson's
  • diagnosis of visual impairment

Other

  • diagnosis of schizophrenia and intellectual disability
  • diagnosis of multiple sclerosis
  • pregnancy or breastfeeding during enrollment screening

Who the study is looking for

  • 30-65 years old
  • body mass index (BMI) of 25-35
  • participants with genetic data available
  • participants with a valid recontacting informed consent to their biobank

Age in the registry: 35 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Finnish Clinical Biobank Tampere
Coordinator of this site? Confirm its status
TampereFinlandUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.